Intravitreal Bevacizumab for Treatment of Refractory Central Serous Choroidoretinopathy

• 발행기관: 대한안과학회
• 저자명: Morteza Entezari Alireza Ramezani Mehdi Yaseri
• 간행물 정보: 『The Korean Journal of Ophthalmology』Vol.26 No.2, 139~142쪽, 전체 4쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2012.04.30

영문 초록

In a clinical case series, 5 patients with not-resolved central serous choroidoretinopathy (CSC) lasting more than 1 year received one intravitreal bevacizumab injection (IVB, 1.25 mg) injection. All patients underwent a through ophthalmic examination 1 day, 1 week, and 1, 2, and 6 months after the injection. Best corrected visual acuity (BCVA) and central macular thickness were compared before and after treatment by optical coherence tomography. Mean BCVA was improved significantly (p = 0.020) from 0.60 ± 0.25 to 0.50 ± 0.18 and 0.29 ± 0.19 logarithm of minimum angle of resolution at 6 and 18 weeks, respectively. Central macular thickness was also decreased significantly (p = 0.010) from 370 ± 65 to 208 ± 23 μm at 4 months. No recurrence was occurred during follow-up. IVB injection may have beneficial effect in the treatment of refractory CSC.

목차

Case Report

Discussion

Conflict of Interest

References

키워드

Bevacizumab Central serous choroidoretinopathy Optical coherence tomography